AVDL - Avadel Pharmaceuticals: Inflection Point Ahead

2024-06-16 10:38:06 ET

Summary

• Avadel Pharmaceuticals is a small-cap biopharma company headquartered in Dublin, Ireland.
• The company's primary asset is LUMRYX, which has the potential to be a 'best of breed' compound in a large market.
• Currently, Avadel is locked in a pivotal litigation battle with Jazz Pharmaceuticals, which it looks more and more likely to prevail.
• This sets up a potential key inflection point for the company and its shareholders.  An updated analysis around Avadel Pharmaceuticals follows in the paragraphs below.

Today, we are putting small-cap biopharma Avadel Pharmaceuticals ( AVDL ) in the spotlight as the company has potential catalysts ahead of it and is at an inflection point. Avadel Pharmaceuticals is headquartered in Dublin, Ireland. The company's primary asset is a compound called LUMRYZ, which is a formulation of sodium oxybate and is taken once a day. In the summer of 2022, the FDA gave its ' tentative ' approval to LUMRYZ for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. Final approval was granted in May of 2023. The stock currently trades just below $16.00 a share and sports an approximate market capitalization of $1.5 billion. ...

For further details see: